Anne Beaven

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

Carlos A. Ramos, Natalie S. Grover, Anne Beaven et al. · Journal of Clinical Oncology · 2020 · 366 citations · Full text

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

John F. Seymour, Shuo Ma, Danielle M. Brander et al. · The Lancet Oncology · 2017 · 321 citations · Full text

Phase 1B, Lymphoid Neoplasia, Hematological Malignancy +10

The Genetic Basis of Hepatosplenic T-cell Lymphoma

Matthew McKinney, Andrea B. Moffitt, Philippe Gaulard et al. · Cancer Discovery · 2017 · 195 citations · Full text

Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Owen A. O’Connor, Muhıt Özcan, Eric D. Jacobsen et al. · Journal of Clinical Oncology · 2019 · 143 citations · Full text

A phase <scp>II</scp> study of cyclophosphamide, etoposide, vincristine and prednisone ( <scp>CEOP</scp> ) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma ( <scp>PTCL</scp> ): final results from the T‐ cell consortium trial

Ranjana H. Advani, Stephen M. Ansell, Mary Jo Lechowicz et al. · British Journal of Haematology · 2015 · 87 citations · Full text